Amidst rumors that Novartis might be interested in an acquisition, The Medicines Company announced data from ORION-10, the second of three 19-month Phase III trials of inclisiran for lowering cholesterol.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,